| Drug ID: | Drug52 |
|---|---|
| Drug Name: | Iron |
| CID: | 23925 |
| DrugBank ID: | DB01592 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | NO |
| Other Approved: | YES |
| Identifier: | NCT01017614, , NCT03441893 |
| Molecular Formula: | Fe |
| Molecular Weight: | 55.84 g/mol |
| Isomeric SMILES: | [Fe] |
| Synonyms: | IRON; 7439-89-6; Iron, elemental; Ferrum; Iron powder; Remko; Armco iron; Ferrovac E; Ancor B; hierro |
| Phase 0: | 4 |
| Phase 1: | 19 |
| Phase 2: | 46 |
| Phase 3: | 81 |
| Phase 4: | 92 |
| Description: | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt472 | 23925 | Iron | 3040 | HBA2 | Homo sapiens (human) | Activator | |
| dt473 | 23925 | Iron | 7037 | TFRC | Homo sapiens (human) | 16564538 | None |
| dt474 | 23925 | Iron | 54583 | EGLN1 | Homo sapiens (human) | 16649251 | None |
| dt475 | 23925 | Iron | 55869 | HDAC8 | Homo sapiens (human) | 16681389 | Cofactor |
| dt476 | 23925 | Iron | 51327 | AHSP | Homo sapiens (human) | 16901899 | None |
| dt477 | 23925 | Iron | 2395 | FXN | Homo sapiens (human) | 16911956 | None |
| dt478 | 23925 | Iron | 2495 | FTH1 | Homo sapiens (human) | 17070541 | None |
| dt479 | 23925 | Iron | 2237 | FEN1 | Homo sapiens (human) | 20622253 | None |
| dt480 | 23925 | Iron | 79661 | NEIL1 | Homo sapiens (human) | 20622253 | None |
| dt481 | 23925 | Iron | 252969 | NEIL2 | Homo sapiens (human) | 20622253 | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05581420 | Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy. | NA | UNKNOWN | Leiden University Medical Center | Inflammatory Bowel Diseases | DRUG: Ferrous fumarate|DRUG: MonoFer | Details |
| NCT05456932 | Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease | PHASE4 | UNKNOWN | Leiden University Medical Center | Inflammatory Bowel Diseases|Iron-deficiency|Iron … | DRUG: Intravenous iron|DRUG: Ferric maltol|DRUG: … | Details |
| NCT07141238 | Microplastic Analysis in Pediatric Inflammatory Bowel Disease | NULL | RECRUITING | Medical University of Gdansk | Crohn Disease|Pediatric Inflammatory Bowel Diseas… | OTHER: Environmental microplastic exposure | Details |
| NCT05225545 | Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis | PHASE3 | UNKNOWN | American University of Beirut Medical Center | Anemia, Iron Deficiency|Ulcerative Colitis | DRUG: Sucrosomial Iron|DRUG: Oral Iron | Details |
| NCT05176795 | Host-microbiota-environment Interactions | NULL | TERMINATED | University Hospital, Clermont-Ferrand | Juvenile Idiopathic Arthritis|Diabetes type1|Infl… | OTHER: Stool sample | Details |
| NCT04960826 | Study of an Environmental Risk Factor in Crohn's Disease | NULL | RECRUITING | University Hospital, Lille | Inflammatory Bowel Diseases | None | Details |
| NCT04587141 | Clinical Burden of Anemia in Inflammatory Bowel Disease: Therapeutic Trial | PHASE3 | UNKNOWN | Fondazione IRCCS Policlinico San Matteo di Pavia | Iron Deficiency Anemia|Inflammatory Bowel Diseases | DRUG: Sucrosomial iron|DRUG: Ferric Gluconate|DRU… | Details |
| NCT04565821 | Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe | NA | ACTIVE_NOT_RECRUITING | Massachusetts General Hospital | Inflammatory Disease|Permeability; Increased|Croh… | DEVICE: IPD Probe via TNIT | Details |
| NCT04318405 | Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE). | NULL | COMPLETED | Pierre Fabre Pharma AG | Iron-Deficiency Anemia|Iron-Deficiency | DRUG: Iron isomaltoside 1000 | Details |
| NCT07380022 | Acceptability, Adherence, and Impact on the Bioavailability of Iron and Zinc of the Dietary Supplements Goodphyte IB Defense and Goodphyte Immunity in Adults With Chronic Diseases. | NA | RECRUITING | University of Thessaly | IBD|Hypertension (HTN)|Multiple Sclerosis|Anemia|… | DIETARY_SUPPLEMENT: Dietary supplement interventi… | Details |
| NCT04123990 | Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease | NA | UNKNOWN | VIFORFRANCE | Intestinal Disease | DIAGNOSTIC_TEST: Iron status testing | Details |
| NCT03872622 | Intestinal Response Patterns to Microbial Signals | NA | COMPLETED | Sheba Medical Center | CD - Crohn's Disease | OTHER: Blood tests, intestinal biopsies, stool sa… | Details |
| NCT03466983 | A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease | PHASE4 | COMPLETED | Pharmacosmos A/S | IBD | DRUG: Iron Isomaltoside|DRUG: Ferric Carboxymalto… | Details |
| NCT03457571 | Clinical Observational Study: IBD Patients With Restless-legs-syndrome and Iron Deficiency Syndrome | NULL | COMPLETED | Charite University, Berlin, Germany | Inflammatory Bowel Diseases|Restless Legs Syndrom… | None | Details |
| NCT03376230 | Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease | NULL | TERMINATED | University Hospital, Lille | Inflammatory Bowel Diseases | OTHER: Collect of blood, urines, and intestinal b… | Details |
| NCT03282903 | The PRognostic Effect of Environmental Factors in Crohn's and Colitis | NULL | COMPLETED | University of Edinburgh | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | None | Details |
| NCT03247816 | Feraccru® Real World Effectiveness Study in Hospital Practice ( FRESH ) | NULL | COMPLETED | Shield Therapeutics | Anemia, Iron Deficiency|Inflammatory Bowel Diseas… | None | Details |
| NCT03136419 | Microbiota and Immune microEnvironment in Pouchitis | NA | UNKNOWN | University of Padova | Pouchitis|Ulcerative Colitis|Ileal Pouch | DIETARY_SUPPLEMENT: Lactobacillus casei DG|DIETAR… | Details |
| NCT02965209 | European Novel Motorized Spiral Endoscopy Trial | NA | COMPLETED | Evangelisches Krankenhaus Düsseldorf | Disorder of Small Intestine|Gastrointestinal Hemo… | PROCEDURE: motorized spiral enteroscopy | Details |
| NCT02774057 | Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD | PHASE4 | UNKNOWN | American University of Beirut Medical Center | Iron Deficiency Anemia|Inflammatory Bowel Disease | DRUG: Captafer®|DRUG: Iron Sulfate | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Diet as an environmental trigger in inflammatory bowel disease: a retrospective…
PMID: 32450704
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Comment in Inflamm Bowel Dis. 2020 Oct 23;26(11):e141. BACKGROUND: Inflammatory bowel disease (IBD) frequently affects women during their repro…
Trends in Anemia, Iron, Therapy, and Transfusion in Hospitalized Pediatric Pati…
PMID: 32444225
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease (IBD) is a chronic relapsing inflammation in the gastrointestinal tract. Biological therapeutics and orally available sma…
Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
PMID: 32438763
Year: 2020
Relationship Type:
Association
Score: 6.5
Not found
Biomarkers and Hematological Indices in the Diagnosis of Iron Deficiency in Chi…
PMID: 32397525
Year: 2020
Relationship Type:
Association
Score: 6.5
OBJECTIVES: Parents have a central role in the management of children with inflammatory bowel disease (IBD). Alterations in parental psychological …
Iron Absorption in Celiac Disease and Nutraceutical Effect of 7-Hydroxymataires…
PMID: 32349426
Year: 2020
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Using therapeutic drug monitoring [TDM] in adult patients with inflammatory bowel disease [IBD] remains controversial. We conducted a …
Comparative accuracy of ferritin, transferrin saturation and soluble transferri…
PMID: 32323356
Year: 2020
Relationship Type:
Association
Score: 6.5
BACKGROUND: Th subsets particularly T helper 17 and regulatory T cells play a critical role in immune balance in colonic mucosa of Inflammatory Bowe…
Rewilding Nod2 and Atg16l1 Mutant Mice Uncovers Genetic and Environmental Contr…
PMID: 32209431
Year: 2020
Relationship Type:
Association
Score: 6.5
Protein tyrosine phosphatase nonreceptor type 2 (PTPN2) plays a critical role in the pathogenesis of inflammatory bowel diseases (IBD). Mice lacking…
Advances in the understanding of the intestinal micro-environment and inflammat…
PMID: 32106123
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Research on inflammatory bowel disease (IBD) has produced mounting evidence for the modulation of microRNAs (miRNAs) during pathogenesis. MiRNAs are…
Increasing incidence of inflammatory bowel disease in children and adolescents:…
PMID: 32024322
Year: 2020
Relationship Type:
Association
Score: 6.5
OBJECTIVES: Hirschsprung disease (HSCR) has previously been associated with inflammatory bowel disease (IBD). There are no data to show how common t…
Environmental exposures and the risk of inflammatory bowel disease: a case-cont…
PMID: 31851095
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Immunoglobulins (Igs) form a cornerstone of mucosal immunity. In the gastrointestinal tract, secretory IgA and IgM bind to commensal microorganisms …
Environmental Factors in Romanian and Belgian Patients with Inflammatory Bowel …
PMID: 31798738
Year: 2019
Relationship Type:
Treatment
Score: 6.5
Patients suffering from inflammatory bowel diseases (IBD) are at increased risk of infections, mainly due to immunosuppressive treatment. Moreover, …
Increased DMT1 and FPN1 expression with enhanced iron absorption in ulcerative …
PMID: 31721611
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Erratum in J Agric Food Chem. 2020 Jan 8;68(1):439. l-Arabinose is a monosaccharide extracted from plants or fibers, which is known to have a v…
Improvement of Health-Related Quality of Life in Children with Inflammatory Bow…
PMID: 31719814
Year: 2019
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Sleep is essential in maintaining health and quality of life. Inflammatory bowel disease (IBD) patients suffer from poor sleep quality. …
Genetic and Environmental Considerations for Inflammatory Bowel Disease
PMID: 31676058
Year: 2019
Relationship Type:
Treatment
Score: 6.5
A full understanding of the presentation and work-up of inflammatory bowel disease is necessary to ensure appropriate treatment of this complex dise…
Inflammation, but Not the Underlying Disease or Its Location, Predicts Oral Iro…
PMID: 31665264
Year: 2020
Relationship Type:
Association
Score: 6.5
Comment on Dig Dis Sci. 2021 Dec;66(12):4178-4190.
Indications and associated factors for prescribing intravenous iron supplementa…
PMID: 31568551
Year: 2019
Relationship Type:
Association
Score: 6.5
INTRODUCTION: Sunlight exposure is the main source of vitaminD. Our aim was to describe both sun exposure and sun protection behaviour in a series o…
A Proresolving Peptide Nanotherapy for Site-Specific Treatment of Inflammatory …
PMID: 31559126
Year: 2019
Relationship Type:
Treatment
Score: 6.5
Infliximab (IFX) is an intravenously administered monoclonal antibody antagonizing the effects of tumor necrosis factor-alpha (TNF) systemically and…
Environmental, Nutritional, and Socioeconomic Determinants of IBD Incidence: A …
PMID: 31504350
Year: 2020
Relationship Type:
Treatment
Score: 6.5
A 53-year-old man who had been diagnosed with moderate ulcerative colitis and treated with mesalazine and glucocorticoid steroid was admitted due to…
Safety and Efficacy of Intravenous Iron Sucrose for Iron-Deficiency Anemia in C…
PMID: 31453270
Year: 2019
Relationship Type:
Association
Score: 6.5
OBJECTIVES: Extraintestinal manifestations (EIM) are common complications of inflammatory bowel disease (IBD) associated with morbidity and reduced …
Isolation-by-environment as a driver of genetic differentiation among populatio…
PMID: 31427616
Year: 2019
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND OBJECTIVES: The exosomes released by mesenchymal stromal cells (MSCs) in classical FBS-containing media have been demonstrated as an …